25786-09-8

Basic information

• Product Name: N1-(4-AMINOPHENYL)-N2,N2-DIMETHYLGLYCINAMIDE
• Synonyms: N1-(4-AMINOPHENYL)-N2,N2-DIMETHYLGLYCINAMIDE;UKRORGSYN-BB BBV-025914;N~1~-(4-aminophenyl)-N~2~,N~2~-dimethylglycinamide(SALTDATA: FREE)
• CAS NO: 25786-09-8
• Molecular Formula: C₁₀H₁₅N₃O
• Molecular Weight: 193.25
• Mol File: 25786-09-8.mol
• Article Data: 7

Chemical Properties

• Boiling Point: 304.059°C at 760 mmHg
• Flash Point: 137.691°C
• Appearance: /
• Density: 1.171g/cm³
• Vapor Pressure: 0.001mmHg at 25°C
• Refractive Index: 1.617
• Storage Temp.: Hygroscopic, -20°C Freezer, Under inert atmosphere
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 14.09±0.70(Predicted)
• CAS DataBase Reference: N1-(4-AMINOPHENYL)-N2,N2-DIMETHYLGLYCINAMIDE(CAS DataBase Reference)
• NIST Chemistry Reference: N1-(4-AMINOPHENYL)-N2,N2-DIMETHYLGLYCINAMIDE(25786-09-8)
• EPA Substance Registry System: N1-(4-AMINOPHENYL)-N2,N2-DIMETHYLGLYCINAMIDE(25786-09-8)

Safety Data

• Hazardous Substances Data: 25786-09-8(Hazardous Substances Data)

Usage

General Description

N1-(4-aminophenyl)-N2,N2-dimethylglycinamide, also known as procainamide, is an antiarrhythmic medication used to treat irregular heartbeats. It works by blocking sodium channels in the heart, which helps to control the electrical signals that regulate the heartbeat. Procainamide is also used as a local anesthetic and has been investigated for its potential use in the treatment of malaria. It is available in various forms, including tablets, capsules, and injections, and is generally well-tolerated when used as directed, although it may cause side effects such as nausea, vomiting, and dizziness. It is important to use this medication only under the supervision of a healthcare professional, as it can have serious interactions with other drugs and medical conditions.

InChI:InChI=1/C10H15N3O/c1-13(2)7-10(14)12-9-5-3-8(11)4-6-9/h3-6H,7,11H2,1-2H3,(H,12,14)

Upstream product

• 71026-66-9 N-(tert-butoxycarbonyl)-1,4-phenylenediamine 
• 100-01-6 4-nitro-aniline 
• 25786-08-7 2-dimethylamino-N-(4-nitro-phenyl)-acetamide 
• 17329-87-2 2-chloro-N-(4-nitro-phenyl)-acetamide 

Downstream Products

• 1446421-19-7 N-(4-(3-(4-(bis(2-chloroethyl)amino)phenyl)ureido)phenyl)-2-(dimethylamino)acetamide 
• 1452128-56-1 4-(4-(2-(dimethylamino)acetamido)anilino)quinazoline 
• 921201-90-3 N-(4-azido-phenyl)-2-dimethylamino-acetamide 
• 1622093-57-5 N-(4-(4-((4-(1H-phenanthro[9,10-d]imidazol-2-yl)phenoxy)methyl)-1H-1,2,3-triazol-1-yl)phenyl)-2-(dimethylamino)acetamide 

Relevant articles and documents

Design and synthesis of potent antitumor water-soluble phenyl N-mustard-benzenealkylamide conjugates via a bioisostere approach

A series of new, water-soluble phenyl N-mustard-benzenealkylamide conjugates containing hydrophilic ω-dialkylaminoalkylamide or ω-cyclic aminoalkylamide moieties were synthesized via a bioisostere approach. These compounds have a broad spectrum of antitumor activity against a panel of human tumor cell lines. Of these derivatives, compound 18b effectively suppressed the growth of colon cancer (HCT-116), prostate cancer (PC3), and lung cancer (H460) xenografts. The growth of HCT-116 xenografts was almost completely suppressed when co-treated with compound 18b and 5-fluorouracil. Furthermore, compound 18b can induce DNA cross-linking and cell-cycle arrest at the G2/M phase. Early preclinical studies, including pharmacokinetics in rats, inhibition of the hERG, and 14 days of acute intravenous injection toxicity, suggest that compound 18b is a promising candidate for further preclinical studies.

Synthesis, Antitumor Evaluation and Docking Study of Novel 4-Anilinoquinazoline Derivatives as Potential Epidermal Growth Factor Receptor (EGFR) Inhibitors

-

THERAPEUTIC G-QUADRUPLEX LIGANDS

The invention provides compounds of formula (I): wherein Ar1 is a monocyclic aryl or heteroaryl; X and Y are each independe ntly a group of formula (II): Z is absent, a group of formula (II), optionally substituted C1-7 alkyl, optionally substituted C3-20 heterocyclyl, optionally substituted C5-20 aryl, halo, amino, hydroxy, ether, thio, thioet her, carboxy or cyano; L1 and L2 are each independently selected from NR 3, C2H2, CH2, -O-, -S- and a bond; Ar2 and Ar3 are independently optionally substituted C 5 or C6 aryl or heteroaryl; n is an integer from 1 to 5; R1 and R2 are independently hydrog en, C1-7 alkyl, C3-20 heterocyclyl, or C 5-20 aryl, or R1 and R2, taken together with the nitrogen atom to which they are attached, form a heterocyclic ring having from 3 to 8 ring atoms; R3 is H or C 1-7 alkyl; and provided that at least one of Ar 1, Ar2 and Ar3 is oxazole, triazole or tetrazole. These compounds are thought to bind G -quadruplexes formed in human telomeres and are therefore useful in anti -cancer therapy. The invention also provides pharmaceutical compositions comprising the novel compounds, and methods for their manufacture.